Cargando…

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Deeb, Dorrah, Gao, Xiaohua, Arbab, Ali S., Barton, Kenneth, Dulchavsky, Scott A., Gautam, Subhash C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143824/
https://www.ncbi.nlm.nih.gov/pubmed/21799944
http://dx.doi.org/10.3390/cancers2041779
_version_ 1782208929816641536
author Deeb, Dorrah
Gao, Xiaohua
Arbab, Ali S.
Barton, Kenneth
Dulchavsky, Scott A.
Gautam, Subhash C.
author_facet Deeb, Dorrah
Gao, Xiaohua
Arbab, Ali S.
Barton, Kenneth
Dulchavsky, Scott A.
Gautam, Subhash C.
author_sort Deeb, Dorrah
collection PubMed
description Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity.
format Online
Article
Text
id pubmed-3143824
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-31438242011-07-26 CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer Deeb, Dorrah Gao, Xiaohua Arbab, Ali S. Barton, Kenneth Dulchavsky, Scott A. Gautam, Subhash C. Cancers (Basel) Article Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. MDPI 2010-10-13 /pmc/articles/PMC3143824/ /pubmed/21799944 http://dx.doi.org/10.3390/cancers2041779 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Deeb, Dorrah
Gao, Xiaohua
Arbab, Ali S.
Barton, Kenneth
Dulchavsky, Scott A.
Gautam, Subhash C.
CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title_full CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title_fullStr CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title_full_unstemmed CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title_short CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
title_sort cddo-me: a novel synthetic triterpenoid for the treatment of pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143824/
https://www.ncbi.nlm.nih.gov/pubmed/21799944
http://dx.doi.org/10.3390/cancers2041779
work_keys_str_mv AT deebdorrah cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer
AT gaoxiaohua cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer
AT arbabalis cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer
AT bartonkenneth cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer
AT dulchavskyscotta cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer
AT gautamsubhashc cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer